Total Payments
$2,212
2024 Payments
$38.46
Companies
23
Transactions
112
Medicare Patients
13,388
Medicare Billing
$659,907
Payment Breakdown by Category
Food & Beverage$1,920 (86.8%)
Education$291.76 (13.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,920 | 108 | 86.8% |
| Education | $291.76 | 4 | 13.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $434.43 | 29 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $287.07 | 13 | $0 (2021) |
| Astellas Pharma US Inc | $263.98 | 3 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $186.27 | 9 | $0 (2023) |
| PFIZER INC. | $172.11 | 9 | $0 (2023) |
| ABBVIE INC. | $113.93 | 7 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $113.26 | 9 | $0 (2021) |
| Novo Nordisk Inc | $99.47 | 6 | $0 (2020) |
| Lilly USA, LLC | $92.94 | 5 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $87.77 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38.46 | 2 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($23.85) |
| 2023 | $120.78 | 8 | ABBVIE INC. ($32.19) |
| 2022 | $152.26 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($74.54) |
| 2021 | $542.58 | 29 | Boehringer Ingelheim Pharmaceuticals, Inc. ($172.99) |
| 2020 | $685.19 | 35 | Janssen Pharmaceuticals, Inc ($201.13) |
| 2019 | $130.82 | 5 | E.R. Squibb & Sons, L.L.C. ($59.20) |
| 2018 | $245.30 | 9 | Astellas Pharma US Inc ($74.99) |
| 2017 | $296.81 | 14 | Astellas Pharma US Inc ($99.99) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: Gastroenterology | ||||||
| 04/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: NEUROSCIENCE | ||||||
| 08/31/2023 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: PAIN | ||||||
| 07/28/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: NEUROSCIENCE | ||||||
| 06/30/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $13.66 | General |
| 05/30/2023 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Diabetes | ||||||
| 05/17/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Diabetes | ||||||
| 04/27/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: DIABETES | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: DIABETES | ||||||
| 12/05/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/31/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/20/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: DIABETES | ||||||
| 08/09/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/14/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: DIABETES | ||||||
| 03/31/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: DIABETES | ||||||
| 03/08/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: NEUROSCIENCE | ||||||
| 01/25/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: DIABETES | ||||||
| 12/02/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: NEUROSCIENCE | ||||||
| 11/23/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: DIABETES | ||||||
| 11/09/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.35 | General |
| Category: Cardiovascular | ||||||
| 11/02/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $3.54 | General |
| Category: DIABETES | ||||||
| 10/19/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 3,059 | 5,788 | $374,489 | $141,930 |
| 2022 | 36 | 3,191 | 6,107 | $465,196 | $163,831 |
| 2021 | 38 | 3,502 | 6,502 | $504,602 | $179,359 |
| 2020 | 40 | 3,636 | 6,581 | $620,160 | $174,786 |
Total Patients
13,388
Total Services
24,978
Medicare Billing
$659,907
Procedure Codes
152
All Medicare Procedures & Services
152 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 591 | 1,660 | $92,395 | $47,221 | 51.1% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 130 | 959 | $43,770 | $24,185 | 55.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 176 | 242 | $21,882 | $12,315 | 56.3% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 97 | 178 | $13,350 | $8,198 | 61.4% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 34 | 34 | $71,026 | $4,531 | 6.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 67 | $5,401 | $3,919 | 72.6% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 29 | 29 | $5,075 | $3,842 | 75.7% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 37 | 40 | $5,800 | $3,831 | 66.0% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 61 | 115 | $7,475 | $2,951 | 39.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 405 | 592 | $2,960 | $2,892 | 97.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 258 | 358 | $8,950 | $2,717 | 30.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 29 | 31 | $5,425 | $2,713 | 50.0% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 28 | 28 | $39,648 | $2,562 | 6.5% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 112 | 113 | $2,825 | $2,474 | 87.6% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 62 | 72 | $5,400 | $2,419 | 44.8% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Facility | 2023 | 15 | 18 | $3,150 | $1,865 | 59.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 30 | 31 | $3,155 | $1,804 | 57.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 63 | 113 | $3,497 | $1,548 | 44.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 13 | 13 | $2,275 | $1,525 | 67.0% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 54 | 57 | $1,425 | $1,397 | 98.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 54 | 55 | $1,100 | $1,078 | 98.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 17 | 29 | $1,450 | $1,061 | 73.2% |
| 99315 | Nursing facility discharge day management, 30 minutes or less | Facility | 2023 | 16 | 17 | $1,785 | $1,020 | 57.1% |
| 87275 | Detection test by immunofluorescent technique for influenza b virus | Office | 2023 | 56 | 62 | $2,170 | $744.00 | 34.3% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 120 | 176 | $1,760 | $693.44 | 39.4% |
About Dr. Tom Longest, MD
Dr. Tom Longest, MD is a Family Medicine healthcare provider based in Bruce, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851477079.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tom Longest, MD has received a total of $2,212 in payments from pharmaceutical and medical device companies, with $38.46 received in 2024. These payments were reported across 112 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($1,920).
As a Medicare-enrolled provider, Longest has provided services to 13,388 Medicare beneficiaries, totaling 24,978 services with total Medicare billing of $659,907. Data is available for 4 years (2020–2023), covering 152 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Bruce, MS
- Active Since 10/31/2006
- Last Updated 01/23/2025
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1851477079
Products in Payments
- JARDIANCE (Drug) $369.69
- XARELTO (Drug) $287.07
- FARXIGA (Drug) $186.27
- CHANTIX (Drug) $135.95
- VRAYLAR (Drug) $99.90
- ELIQUIS (Drug) $87.77
- Vascepa (Drug) $82.45
- APTIOM (Drug) $71.98
- Ozempic (Drug) $64.37
- BASAGLAR (Drug) $42.87
- GEMTESA (Drug) $41.28
- TRULICITY (Drug) $34.67
- Precision Flow (Device) $32.05
- STIOLTO (Drug) $27.78
- UBRELVY (Drug) $25.40
- XIFAXAN (Drug) $23.85
- PREMARIN (Drug) $22.76
- SAMSCA (Drug) $22.20
- Otezla (Drug) $20.87
- Tresiba (Drug) $17.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.